RESULTS OF THE MRC MYELOMATOSIS TRIALS FOR PATIENTS ENTERED SINCE 1980

被引：50

作者：

MACLENNAN, ICM

KELLY, K

CROCKSON, RA

COOPER, EH

CUZICK, J

CHAPMAN, C

机构：

来源：

HEMATOLOGICAL ONCOLOGY | 1988年 / 6卷 / 02期

关键词：

D O I：

10.1002/hon.2900060215

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：145 / 158

页数：14

共 21 条

[1]

ALBERTS DS, 1976, LANCET, V1, P926

[2]

ALEXANIAN R, 1983, BLOOD, V62, P572

[3] EFFECTIVE TREATMENT OF ADVANCED MULTIPLE-MYELOMA REFRACTORY TO ALKYLATING-AGENTS [J].

BARLOGIE, B ;

SMITH, L ;

ALEXANIAN, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (21) :1353-1356

[4]

BRANDES LJ, 1982, CANCER TREAT REP, V66, P1413

[5] PROXIMAL RENAL TUBULAR FUNCTION IN MYELOMATOSIS - OBSERVATIONS IN THE FOURTH MEDICAL-RESEARCH-COUNCIL TRAIL [J].

COOPER, EH ;

FORBES, MA ;

CROCKSON, RA ;

MACLENNAN, ICM .

JOURNAL OF CLINICAL PATHOLOGY, 1984, 37 (08) :852-858

[6] THE PROGNOSTIC VALUE OF SERUM BETA-2 MICROGLOBULIN COMPARED WITH OTHER PRESENTATION FEATURES IN MYELOMATOSIS - (A REPORT TO THE MEDICAL-RESEARCH-COUNCILS WORKING PARTY ON LEUKEMIA IN ADULTS) [J].

CUZICK, J ;

COOPER, EH ;

MACLENNAN, ICM .

BRITISH JOURNAL OF CANCER, 1985, 52 (01) :1-6

[7]

DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO

[8]

2-U

[9] VINDESINE THERAPY IN MELPHALAN-RESISTANT MULTIPLE-MYELOMA [J].

HOUWEN, B ;

OCKHUIZEN, T ;

MARRINK, J ;

NIEWEG, HO .

EUROPEAN JOURNAL OF CANCER, 1981, 17 (02) :227-232

[10] ISOELECTRIC POINTS OF URINARY LIGHT-CHAINS IN MYELOMATOSIS - ANALYSIS IN RELATION TO NEPHROTOXICITY [J].

JOHNS, EA ;

TURNER, R ;

COOPER, EH ;

MACLENNAN, ICM .

JOURNAL OF CLINICAL PATHOLOGY, 1986, 39 (08) :833-837

← 1 2 3 →